Control guideline for public health units

Public health priority: Routine.

PHU response: Enter confirmed and probable cases on NCIMS within 5 working days.

Case management: Responsibility of treating doctor. Case should not attend work, school, preschool or childcare for 9 days from onset of swelling or until fully recovered, whichever is sooner.

Contact management: None routinely.

VersionDateRevised byChangesApproval
1.02004CDNAInitial case definitionCDNA
2.0 1 January 2022 CDNA Inclusion of a probable case definition

Additional detail to laboratory definitive evidence point 3 criterion and inclusion of a footnote to allow recently vaccinated cased to potentially be considered as confirmed cases

Laboratory suggestive evidence moved and adjusted to form part of the probable case definition

Adjustment to the clinical evidence criteria

CDNA

Last updated: 01 July 2022

On this page

1. Reason for surveillance

To monitor the epidemiology of the disease and so inform the development of better prevention strategies.

2. Case definition

Case definitions can be found on Department of Health - Mumps case definition.

Reporting

Both confirmed and probable cases should be notified.

Confirmed case

A confirmed case requires laboratory definitive evidence.

Laboratory definitive evidence

  • Isolation of mumps virus*, or
  • Detection of mumps virus by NAT*, or
  • IgG seroconversion or a significant increase in antibody level such as a fourfold or greater rise in titre to mumps virus except if the case has received a mumps-containing vaccine eight days to eight weeks prior to specimen collection.(Note: paired sera must be tested in parallel).

*If mumps vaccine has been given in the 25 days prior to illness onset wild-type virus must be detected to be classified as a confirmed case. Vaccine-associated mumps illness (genotype A) is not notifiable, but rather should be reported as an adverse event following immunisation.

Probable case

A probable case requires either:

  • laboratory suggestive evidence and clinical evidence, or
  • both clinical and epidemiological evidence.

Laboratory suggestive evidence

Detection of mumps-specific IgM antibody, except

  • if ruled out by more specific mumps IgM serology testing at a jurisdictional public health laboratory or
  • if the case has received a mumps-containing vaccine in the eight days to eight weeks prior to specimen collection

Clinical evidence

A clinically compatible illness (e.g. swelling of the parotid or other salivary glands lasting at least 2 days, or orchitis) without other apparent cause.

Epidemiological evidence

An epidemiological link is established when there is:

  • contact between two people involving a plausible mode of transmission at a time when:
    • one of them is likely to be infectious (6-7 days before onset of overt parotitis to 9 days after), and
    • the other has an illness which starts within approximately 12 to 25 days after this contact, and
  • at least one case in the chain of epidemiologically linked cases (which may involve many cases) is laboratory confirmed.

3. Notification criteria and procedure

Mumps is to be notified by:

  • laboratories on microbiological confirmation (ideal reporting by routine mail)
  • school principals and directors of child care facilities (ideal reporting by telephone on same day of notification).

Only confirmed cases should be entered onto NCIMS.

4. The disease

Infectious agent

The mumps virus.

Mode of transmission

Mumps is transmitted by droplet infection and direct contact with the saliva of infected persons.

Timeline

The typical incubation period is 16 to 18 days (range 12 to 25 days).

Mumps is communicable from about 6-7 days before onset of overt parotitis to 9 days after onset. Maximum infectiousness occurs from 2 days before to 4 days after onset of illness.

Clinical presentation

There is often a prodromal illness of low-grade fever, anorexia, malaise, and headache. The case may report earache followed by tenderness and visible swelling of one or both parotid glands and sometimes other salivary glands.

Approximately one third of cases develop a respiratory tract infection without salivary gland swelling.

25% of postpubertal males develop orchitis (usually unilateral). 5% of postpubertal females develop oophritis. Infertility following gonadal involvement is rare.

Meningitis occurs in 1 to 10% of cases and mumps encephalitis occurs in approximately 0.1% of cases. CSF pleocytosis occurs in 50% of cases (many of whom don't have symptoms of meningitis)

Rare clinical manifestations of mumps include migratory polyarthritis, pancreatitis, nephritis and myocarditis.

Infection in the first trimester of pregnancy is associated with spontaneous abortion. Mumps virus crosses the placenta but does not cause congenital malformations.​

5. Managing single notifications

Response times

Data entry

Within 5 working days of notification enter on NCIMS confirmed cases only.

Response procedure

The response to a notification will normally be carried out in collaboration with the case's health carers. Regardless of who does the follow-up, PHU staff should ensure that action has been taken to:

  • confirm results of relevant pathology tests, or recommend the tests be done
  • for cases without PCR results, collect information on vaccination status (including timing of recent vaccination) and symptoms consistent with clinical case definition.

Where a cluster of cases occurs consider initiating a public health investigation to identify people who are not fully vaccinated.

Case management

Cases requiring hospitalisation should be managed using droplet precautions.

Treatment

Supportive only.

Education

The case or care-giver should be informed about the nature of the infection and the mode of transmission.

Isolation and restriction

Recommend exclusion from work, school, preschool, child care or other settings where there are susceptible individuals, especially young children and infants, for 9 days from the onset of swelling.

Environmental evaluation

None usually required.

Contact management

None.


Contact page owner: Vaccine Preventable Diseases